Clinical win gives Verona a kiss of life
For Verona’s long-suffering shareholders today brought an unexpected clinical success with ensifentrine.
As Nash shifts again, the focus remains on Genfit’s big readout
Genfit investors, who early next year will see the Resolve-It study yield data, digest further developments in the Nash space.
The other shoe drops for Gossamer’s GB001
Novartis’s similarly acting fevipiprant had failed in asthma in October, and today it fails in the more important severe setting.
Breaking down Beigene’s latest deal with the west
A multifaceted tie-up effectively gives Beigene a net $1.5bn fund-raising and several Amgen drugs to sell locally.
Go or no go? Agile and Lipocine hope to make it third time lucky
Smaller projects dominate the list, but this doesn’t make them any less important for November’s hopefuls.
Triple meeting – clinical data, and competition, loom for Mirati
Mirati pulls a rabbit out of its hat, but the conference will serve up three new competitors too.
As the heat rises, Clovis turns to radionuclides
The beleaguered drug maker has licensed a preclinical FAP-directed radiopharmaceutical, a target that has made little progress.
Should the diabetes development road end for Sanofi?
Sanofi has said goodbye to Lexicon, but after years of failing to keep up with rivals, there is scope for the French drug maker to make more drastic cuts to its diabetes…
